Evidence map›Paper›PMID 27550776›Full record

ArticleSchizophrenia bulletin2017

Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.

Juan R Bustillo, Thomas Jones, Hongji Chen, Nicholas Lemke, Christopher Abbott, Clifford Qualls, Shannon Stromberg, Jose Canive, Charles Gasparovic

Abstract read
In one paragraph

Article in Schizophrenia bulletin, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juan R BustilloDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Thomas JonesDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Hongji ChenDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Nicholas LemkeDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Christopher AbbottDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Clifford QuallsDepartment of Mathematics & Statistics, University of New Mexico, Albuquerque, NM, USA.
Shannon StrombergDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Jose CaniveDepartment of Psychiatry, University of New Mexico, Albuquerque, NM, USA.
Charles GasparovicMind Research Network, Albuquerque, NM, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glutamine plus glutamate (Glx), as well as N-acetylaspartate compounds (NAAc, N-acetylaspartate plus N-acetyl-aspartyl-glutamate), a marker of neuronal viability, can be quantified with proton magnetic resonance spectroscopy (1H-MRS). We used 1H-MRS imaging to assess Glx and NAAc, as well as total-choline (glycerophospho-choline plus phospho-choline), myo-inositol and total-creatine (creatine plus phosphocreatine) from an axial supraventricular slab of gray matter (GM, medial-frontal and medial-parietal) and white matter (WM, bilateral-frontal and bilateral-parietal) voxels. Schizophrenia subjects (N = 104) and healthy controls (N = 97) with a broad age range (16 to 65) were studied. In schizophrenia, Glx was increased in GM (P < .001) and WM (P = .01), regardless of age. However, with greater age, NAAc increased in GM (P < .001) but decreased in WM (P < .001) in schizophrenia. In patients, total creatine decreased with age in WM (P < .001). Finally, overall cognitive score correlated positively with WM neurometabolites in controls but negatively in the schizophrenia group (NAAc, P < .001; and creatine [only younger], P < .001). We speculate the results support an ongoing process of increased glutamate metabolism in schizophrenia. Later in the illness, disease progression is suggested by increased cortical compaction without neuronal loss (elevated NAAc) and reduced axonal integrity (lower NAAc). Furthermore, this process is associated with fundamentally altered relationships between neurometabolite concentrations and cognitive function in schizophrenia.

Indexed as

AdolescentAdultAgedAspartic AcidCholineCreatineFemaleGlutamic AcidGlutamineGray MatterHumansMaleMiddle AgedProton Magnetic Resonance SpectroscopySchizophreniaWhite MatterAspartic AcidCholineCreatineGlutamic AcidGlutamineN-acetylaspartate1H-MRScreatineglutamateN-acetylaspartateschizophreniatotal-choline

Identifiers

PMID27550776
PMCPMC5473520

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.